SCHEMBL29576249

SCHEMBL29576249

CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)CF)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GNPAT O15228 1/20 0.44
CASP3 P42574 9/20 0.43
CASP8 Q14790 5/20 0.43
CASP7 P55210 5/20 0.43
CASP1 P29466 4/20 0.43
CASP9 P55211 2/20 0.42
CASP6 P55212 1/20 0.42
BACE1 P56817 3/20 0.41
BACE2 Q9Y5Z0 2/20 0.41
ENPEP Q07075 5/20 0.40
BMP1 P13497 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29802276 0.91 ENPEP (0.50) CASP3CASP8CASP1CASP9CASP6
SCHEMBL811845 0.88 CASP1 (0.43) GNPATCASP3CASP7CASP1CASP9
SCHEMBL29586208 0.88 BACE1 (0.46) CASP3CASP8CASP7CASP1BACE1
SCHEMBL29487532 0.88 GNPAT (0.44) GNPATCASP3CASP8CASP7CASP1
SCHEMBL7157952 0.88 GNPAT (0.44) GNPATCASP3CASP8CASP7CASP1
SCHEMBL6534663 0.87 GNPAT (0.54) GNPATCASP3CASP7CASP1CASP9
SCHEMBL7166591 0.87 GNPAT (0.48) GNPATCASP3CASP8CASP7CASP1
SCHEMBL22310788 0.86 GNPAT (0.47) GNPATCASP3CASP8CASP7CASP1
SCHEMBL31634368 0.83 KDM4E (0.51) GNPATCASP3CASP7CASP1CASP9
SCHEMBL7165565 0.82 CASP3 (0.55) CASP3CASP8CASP7CASP1CASP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12576076-B2 Use of HSP70 as a regulator of enzymatic activity Zevra Denmark A/S (DK) 2026-03-17 US disclosed
WO-2025106671-A1 PERSONALIZED PROGENITOR CELLS IMMORTA BIO, INC. (US) 2025-05-22 WO disclosed
US-20250075185-A1 Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells CREATIVE MEDICAL TECHNOLOGIES, INC. (US) 2025-03-06 US disclosed
US-20240307366-A1 USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY ZEVRA DENMARK AS (DK) 2024-09-19 US disclosed
US-11938125-B2 Use of Hsp70 as a regulator of enzymatic activity Zevra Denmark A/S (DK) 2024-03-26 US disclosed
EP-4285909-A2 USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY Zevra Denmark A/S (DK) 2023-12-06 EP disclosed
EP-3578195-B1 USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY ZEVRA DENMARK AS (DK) 2023-08-09 EP disclosed
US-20220374361-A1 METHODS FOR INCREASING INTRACELLULAR ACTIVITY OF HSP70 Zevra Denmark A/S (DK) 2022-11-24 US disclosed
US-20220362234-A1 USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY Zevra Denmark A/S (DK) 2022-11-17 US disclosed
CN-109010830-B Application of platelet related inhibitor in preparation of medicine for treating thrombocytopenia 苏州大学 2022-06-07 CN disclosed
US-11304941-B2 Use of HSP70 as a regulator of enzymatic activity ORPHAZYME A/S (DK) 2022-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576076-B2 Use of HSP70 as a regulator of enzymatic activity HSPB1, HSPA1B, HSPD1 GNPAT 2208/4885CASP3 1360/4885CASP8 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.